Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance

Fig. 4

Presence of antigen after transfer of MII.OVA bone marrow induces transient antigen specific tolerance. ac BM (107 cells) from non-Tg and MII.OVA mice was transferred i.v. to B6.SJL mice under low-dose irradiation (300 cGy TBI). Rapamycin (rapa; 0.6 mg/kg) or PBS was administered i.p. for 22 days commencing at BMT. Five or 26 weeks after BMT, CFSE-labeled OT-I T cells (5 × 106) cells were transferred i.v. and 3 days later CFSE dilution determined by flow cytometry of lymph node cells. Data show representative histograms and proliferation index (mean ± SEM) for OT-I in pooled lymph nodes from each group (a) or individual mice at 5 weeks where bars denote mean ± SEM (b) and the level of engraftment in the spleen for individual mice where bars denote mean ± SEM (c) or at 26 weeks (d). Pooled from two experiments with 2 mice per group (5 weeks) or from a single experiment with 2 mice per group (26 weeks). e, f Whole BM, HPC (Lin–ve,c-kit+; 2 × 105 cells) and HPC-depleted BM (Lin+ve,c-kit; 107 cells from non-transgenic or MII.OVA mice was transferred to B6.SJL (CD45.1+) mice under low-dose irradiation. Four weeks after BMT, CFSE-labeled OT-I T cells (5 × 106) were transferred i.v. and 3 days later CFSE dilution determined by flow cytometry. Data show proliferation index of OT-I cells (e) and engraftment levels in the spleens of individual mice (f) pooled from two experiments. Bars denote mean ± SEM. ANOVA with Tukey’s post test. BM bone marrow, HPC defines lin–ve/c-kit+ve hematopoietic progenitor cells

Back to article page